JP2016506912A5 - - Google Patents

Download PDF

Info

Publication number
JP2016506912A5
JP2016506912A5 JP2015553074A JP2015553074A JP2016506912A5 JP 2016506912 A5 JP2016506912 A5 JP 2016506912A5 JP 2015553074 A JP2015553074 A JP 2015553074A JP 2015553074 A JP2015553074 A JP 2015553074A JP 2016506912 A5 JP2016506912 A5 JP 2016506912A5
Authority
JP
Japan
Prior art keywords
polypeptide
pharmaceutical composition
fgfr3
composition according
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015553074A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016506912A (ja
Filing date
Publication date
Priority claimed from PCT/IB2013/001480 external-priority patent/WO2014111744A1/en
Application filed filed Critical
Publication of JP2016506912A publication Critical patent/JP2016506912A/ja
Publication of JP2016506912A5 publication Critical patent/JP2016506912A5/ja
Withdrawn legal-status Critical Current

Links

JP2015553074A 2013-01-16 2014-01-16 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド Withdrawn JP2016506912A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2013/001480 2013-01-16
PCT/IB2013/001480 WO2014111744A1 (en) 2013-01-16 2013-01-16 A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
PCT/EP2014/050800 WO2014111467A1 (en) 2013-01-16 2014-01-16 A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019021752A Division JP6995069B2 (ja) 2013-01-16 2019-02-08 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド

Publications (2)

Publication Number Publication Date
JP2016506912A JP2016506912A (ja) 2016-03-07
JP2016506912A5 true JP2016506912A5 (https=) 2017-02-16

Family

ID=48289519

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015553175A Withdrawn JP2016506914A (ja) 2013-01-16 2013-01-16 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
JP2015553074A Withdrawn JP2016506912A (ja) 2013-01-16 2014-01-16 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
JP2019021752A Expired - Fee Related JP6995069B2 (ja) 2013-01-16 2019-02-08 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015553175A Withdrawn JP2016506914A (ja) 2013-01-16 2013-01-16 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019021752A Expired - Fee Related JP6995069B2 (ja) 2013-01-16 2019-02-08 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド

Country Status (19)

Country Link
US (5) US20150344855A1 (https=)
EP (2) EP2945967B1 (https=)
JP (3) JP2016506914A (https=)
KR (3) KR20160002681A (https=)
CN (1) CN105121464B (https=)
AU (2) AU2013373679A1 (https=)
CA (2) CA2898415A1 (https=)
DK (1) DK2945967T3 (https=)
EA (2) EA201591324A1 (https=)
ES (1) ES2796743T3 (https=)
HU (1) HUE049556T2 (https=)
IL (2) IL239810A0 (https=)
MX (2) MX372787B (https=)
PE (1) PE20151664A1 (https=)
PL (1) PL2945967T3 (https=)
PT (1) PT2945967T (https=)
SG (2) SG11201505488XA (https=)
SI (1) SI2945967T1 (https=)
WO (2) WO2014111744A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
EP3242888B8 (en) 2015-01-07 2021-06-02 Pfizer Inc. Soluble fgfr3 decoys for treating skeletal growth disorders
KR101981774B1 (ko) * 2016-04-25 2019-05-27 장부다 Vr 공간에서 사용자 인터페이스를 제공하는 방법, 디바이스 및 기록매체
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
JP7335247B2 (ja) * 2017-09-20 2023-08-29 ファイザー・インク 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置
CN108410803B (zh) * 2018-03-28 2019-02-05 湖南源品细胞生物科技有限公司 一种诱导脂肪干细胞成软骨分化的培养方法和培养液
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
WO2022254319A1 (en) 2021-06-01 2022-12-08 Pfizer Inc. Cell culture method for producing sfgfr3 polypeptide

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
WO1996041620A1 (en) * 1995-06-12 1996-12-27 Yeda Research And Development Co., Ltd. Fgfr3 as a marker for mesenchymal skeletal progenitor cells
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
AU2002235202A1 (en) * 2000-12-18 2002-07-01 Gene Logic, Inc. Treatment of bone disorders by modulation of fgfr3
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
JP2003104908A (ja) * 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
JP4252746B2 (ja) * 2001-10-05 2009-04-08 一和 中尾 軟骨無形成症治療剤
BRPI0203172B8 (pt) * 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
IL156495A0 (en) * 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
ES2374822T3 (es) 2004-02-24 2012-02-22 Allergan, Inc. Ensayo de selección de toxinas botul�?nicas.
EP2083081A1 (en) * 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
EP2083846B1 (en) 2006-09-28 2015-07-15 Hepacore Ltd. N-terminal fgf variants having increased receptor selectivity and uses thereof
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
EP2318529B1 (en) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
MA33208B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
CN101585866B (zh) * 2009-07-02 2011-10-05 中国人民解放军第三军医大学野战外科研究所 调节fgfr3活性的多肽及其筛选方法和应用
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
LT2498799T (lt) 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
RU2012134637A (ru) 2010-01-14 2014-02-20 Йейл Юниверсити Ингибиторы рецепторных тирозинкиназ (rtk) и способы их применения
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
WO2012088608A1 (en) * 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
CN102219860B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
JP6162707B2 (ja) 2011-10-24 2017-07-12 ハロザイム インコーポレイテッド 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
WO2014018673A2 (en) 2012-07-24 2014-01-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US20140030259A1 (en) 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
US11230589B2 (en) 2012-11-05 2022-01-25 Foundation Medicine, Inc. Fusion molecules and uses thereof
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
EP3242888B8 (en) 2015-01-07 2021-06-02 Pfizer Inc. Soluble fgfr3 decoys for treating skeletal growth disorders
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
JP7335247B2 (ja) 2017-09-20 2023-08-29 ファイザー・インク 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置

Similar Documents

Publication Publication Date Title
JP2016506912A5 (https=)
JP6345216B2 (ja) オキシントモジュリンと免疫グロブリン断片とを含む結合体及びその用途
CN104507492B (zh) 治疗高脂血症的包含泌酸调节肽衍生物的组合物
JP2011526886A5 (https=)
JP2016506914A5 (https=)
US20170088598A1 (en) Long-acting oxyntomodulin variants and methods of producing same
HRP20221021T1 (hr) T stanični receptori specifični za kompleks tumorskog antigena ny-eso-1 sa hla-a*02
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
TW201444866A (zh) 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
JP2011524420A5 (https=)
JP2013518115A5 (https=)
EP2916867A2 (en) Compositions and methods for modulating cell signaling
JP2016518351A5 (https=)
RU2014101697A (ru) Коагонисты рецепторов глюкагона/glp-1
MX2013014069A (es) Agonistas de receptor de glp-1/glucagón de acción prolongada.
JP2016527249A5 (https=)
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
NO326298B1 (no) Anvendelse av R'-Glu-Trp-R'' dipeptider i fremstilling av medikamenter
JP2015520184A (ja) ペグ化ｏｘｍ変異体
JP2013518090A5 (https=)
JP2014050390A5 (https=)
JP2017532965A (ja) 抗血管新生活性を有するシンデカン−２のフラグメント
US20220287347A1 (en) Peptides for treating muscle atrophy
CN109328069A (zh) Il-22在治疗坏死性小肠结肠炎中的用途
JP6615504B2 (ja) 高血圧症の予防又は治療用医薬